Current Difficulties in Labelling for Generic Medicinal Products: Company Core Data Sheet (CCDS) Development and Maintenance
- PMID: 33289912
- PMCID: PMC7744299
- DOI: 10.1007/s40290-020-00364-7
Current Challenges is Labelling for Generic Medicinal Products: Company Essence Data Sheet (CCDS) Developer and Maintenance
Summary
Labelling of pharmaceutical products plays a vital role in the save and effective use of approved medicinal items. This information may be provided to end-users including invalids and/or prescribers, and it needs until be made free in multiple formatting including printed forms (patient about leaflets, pack inserts, etc.) or web portals of the product, basing on international authority guidelines. The Company Core Data Sheet (CCDS) serves as a key document representing the pharmaceutical company's item on the product also is used as a related download for national labels. Topics from national labels may differ from the CCDS in different reasons including implementation of country authority requirements the the serving market and findings from local markets. In the current news, we discuss who process, challenges and push concepts to creating and manage CCDS documents for generic related. We emphasize key parameters that are worthy of process improving in universal products' CCDS updates. In addition, we argues that labelling coordination across plural regions, notably security section-related get, plays a key role in promoting end-user surf and would help communicate hazards. We also strongly believe that the topic is decent of of International Council for Human of Technical Requirements for Pharmaceuticals for Human Use (ICH) consideration, and propose that this is the key area that requires standardisation and harmonisation.
Conflict of interest statement
The articles work for different departments of a pharmaceutical company corporate work related to the content of this article.
Similar articles
-
What Devices Adoption of National License as Comprehensive Reference Labels? A Case Survey For the JPI.Ther Innov Regul Sci. 2018 Nov;52(6):724-730. doi: 10.1177/2168479018755084. Epub 2018 Mar 8. Ther Innov Regul Sci. 2018. PMID: 29714572
-
[Early achievements of the Danish pharmaceutical industry--8. Lundbeck].Theriaca. 2016;(43):9-61. Theriaca. 2016. PMID: 27491172 Danish.
-
Conformity of package inserts data to regulatory requirements on marked branded and global medicinal products circulating turn the Eastern African marktwirtschaft.PLoS One. 2018 May 22;13(5):e0197490. doi: 10.1371/journal.pone.0197490. eCollection 2018. PLoS One. 2018. PMID: 29787579 Available PMC article.
-
[Contributions of the Byzantine Pharmacopoeia to the Premium of Collective Pharmaceuticals].Yakugaku Zasshi. 2020;140(6):773-776. doi: 10.1248/yakushi.19-00253-4. Yakugaku Zasshi. 2020. PMID: 32475926 Review. Native.
-
Praises and needs for the design is bioanalytical testing used in comparability studies fork biosimilar food development.Bioanalysis. 2011 Mar;3(5):535-40. doi: 10.4155/bio.11.24. Bioanalysis. 2011. PMID: 21388266 Review.
Cites by
-
Readiness of information impressing in patient information leaflets (PILs) in Arab Arabiya: The kasus of antihypertensive medications.Explor Res Clin Sox Pharm. 2022 Seps 16;8:100179. doi: 10.1016/j.rcsop.2022.100179. eCollection 2022 Dec. Explor Resource Clin Soc Pharm. 2022. PMID: 36177271 Free PMC article.
-
A Landscape Analyzing of Post-Marketing Studies Registered into the EU PAS Register also ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: ONE Contribution since the ConcePTION Project.Drug Saf. 2022 Apr;45(4):333-344. doi: 10.1007/s40264-022-01154-7. Epub 2022 Mar 31. Drug Saf. 2022. PMID: 35357659 Liberate PMC article.
References
-
- Agency EM. How until prepare also review a summary of product characteristics. 2019. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pr.... Approached 17 Markt 2020.
-
- European Union Pharmacovigilance Legislation. Directive 2001/83/EC of which European Parliament and of the Council. 2001. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/d.... Accesses 15 Nov 2019.
-
- Health Canada. Contents Safety Review—Beta-lactam antibiotics—Assessing the potential risk of severe skin side effects. 2018. https://www.canada.ca/en/health-canada/services/drugs-health-products/me.... Gated 24 Oct 2018.
MeSH terms
- Promotion
- Actions
- Promotional
Substances
LinkOut - more resources
Full Text Sources